COVID-19 infection is caused by SARS-CoV-2, which is a highly transmissible and life-threatening strain of coronavirus. Nasal swab is a method used for collecting clinical test samples of nasal secretions. Nasal swabs can be used for analysis of number of infectious diseases such as whooping cough, influenza, SARS, COVID-19, and others. Rising burden of COVID-19 cases across the world has created a huge opportunity for growth of COVID-19 nasal swab market. These nasal swabs can be used in laboratories as well as in the comfort of one’s home. The collection procedure must be carried out with extreme precautions as any contamination of the nasal swab may lead to wrong results. The collected nasal secretion sample is placed into a transporting medium that provides a stable environment to the sample. This transporting liquid medium is subjected to further diagnostic tests to detect the presence of SARS-CoV-2 in the nasal specimen.
Market Dynamics
Market players and private healthcare organizations are focused on conducting research activities for developing more efficient nasal swabs for detection of COVID-19 infection, which could contribute to the growth of the COVID-19 nasal swab test market over the forecast period. For instance, in March 2020, PATH, Mayo Clinic and Bill and Melinda Gates Foundation initiated an observational clinical study to compare the efficiency of foam nasal swabs and polyester nasal swabs in diagnosis of COVID-19 infection. This study was completed in October 2020, and it also focused on observing the trajectory of COVID-19 at different stages of infection.
Market players are focused on launch of products, which is expected to strengthen their position in the global COVID-19 nasal swab test market. For instance, in November 2020, Tata Medical and Diagnostics launched its product TataMD CHECK, a nasal swab test that is able to diagnose COVID-19 within 90 minutes.
Market players are involved in expanding their presence globally by entering into partnership with other companies in order to enhance distribution, this is expected to drive the growth of the COVID-19 nasal swab test market. For instance, in January 2021, iMFLUX, Inc., an American molding company entered into a partnership with Rhinostics, Inc., a Harvard University startup, to develop polypropylene COVID-19 nasal swab, which is cost effective and allows easy collection of nasal secretion.
Key features of the study:
- This report provides an in-depth analysis of global COVID-19 nasal swab test market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global COVID-19 nasal swab test market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Abbott Laboratories, Roche Holding AG, Becton Dickinson & Company, 3M Corporation, BioMerieux SA, Lucira Health, Mesa Biotech, Inc.,Siemens Healthineers AG, QIAGEN N.V., Cepheid, LumiraDx Ltd., Fluidigm Corporation, Quidel Corporation, GenMark Diagnostics, Inc., Sherlock Biosciences, PrivaPath Diagnostics Limited, and OraSure Technologies, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global COVID-19 nasal swab test market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the COVID-19 nasal swab test market
Detailed Segmentation:
- Global COVID-19 Nasal Swab Test Market, By Product Type:
- Foam Tipped Swabs
- Non-Woven
- Others
- Global COVID-19 Nasal Swab Test Market, By Diagnostics Type:
- Molecular Diagnostics
- CRISPR & Biosensors
- Others
- Global COVID-19 Nasal Swab Test Market, By Mode:
- Point-of-Care
- Non Point-of-Care
- Global COVID-19 Nasal Swab Test Market, By End User:
- Hospital & Clinic
- Laboratories & Diagnostics Centers
- Others
- Global COVID-19 Nasal Swab Test Market, By Region:
- North America
- By Product Type:
- Foam Tipped Swabs
- Non-Woven
- Others
- By Diagnostics Type:
- Molecular Diagnostics
- CRISPR & Biosensors
- Others
- By Mode:
- Point-of-Care
- Non Point-of-Care
- By End User:
- Hospital & Clinic
- Laboratories & Diagnostics Centers
- Others
- By Country:
- Latin America
- By Product Type:
- Foam Tipped Swabs
- Non-Woven
- Others
- By Diagnostics Type:
- Molecular Diagnostics
- CRISPR & Biosensors
- Others
- By Mode:
- Point-of-Care
- Non Point-of-Care
- By End User:
- Hospital & Clinic
- Laboratories & Diagnostics Centers
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type:
- Foam Tipped Swabs
- Non-Woven
- Others
- By Diagnostics Type:
- Molecular Diagnostics
- CRISPR & Biosensors
- Others
- By Mode:
- Point-of-Care
- Non Point-of-Care
- By End User:
- Hospital & Clinic
- Laboratories & Diagnostics Centers
- Others
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Foam Tipped Swabs
- Non-Woven
- Others
- By Diagnostics Type:
- Molecular Diagnostics
- CRISPR & Biosensors
- Others
- By Mode:
- Point-of-Care
- Non Point-of-Care
- By End User:
- Hospital & Clinic
- Laboratories & Diagnostics Centers
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type:
- Foam Tipped Swabs
- Non-Woven
- Others
- By Diagnostics Type:
- Molecular Diagnostics
- CRISPR & Biosensors
- Others
- By Mode:
- Point-of-Care
- Non Point-of-Care
- By End User:
- Hospital & Clinic
- Laboratories & Diagnostics Centers
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Foam Tipped Swabs
- Non-Woven
- Others
- By Diagnostics Type:
- Molecular Diagnostics
- CRISPR & Biosensors
- Others
- By Mode:
- Point-of-Care
- Non Point-of-Care
- By End User:
- Hospital & Clinic
- Laboratories & Diagnostics Centers
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Abbott Laboratories*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Roche Holding AG
- Becton Dickinson & Company
- 3M Corporation
- BioMerieux SA
- Lucira Health
- Mesa Biotech, Inc.
- Siemens Healthineers AG
- QIAGEN N.V.
- Cepheid
- LumiraDx Ltd.
- Fluidigm Corporation
- Quidel Corporation
- GenMark Diagnostics, Inc.
- Sherlock Biosciences
- PrivaPath Diagnostics Limited
- OraSure Technologies, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
